Corcept Therapeutics | CORT

Stock Price
69.36
Daily Change
-0.01 -0.01%
Monthly
-1.64%
Yearly
101.75%
Q3 Forecast
68.78

Peers Price Chg Day Year Date
Acadia Pharmaceuticals 25.26 -0.24 -0.94% 57.19% Sep/05
Aurora Cannabis 6.78 0.09 1.35% -7.50% Sep/05
ANI Pharmaceuticals 95.35 -0.65 -0.68% 57.58% Sep/05
Ardelyx 6.52 -0.05 -0.76% 16.43% Sep/05
BioMarin Pharmaceutical 57.77 1.02 1.80% -31.29% Sep/05
Bristol-Myers Squibb 47.14 0.45 0.96% -3.28% Sep/05
Corcept Therapeutics 69.36 -0.01 -0.01% 101.75% Sep/05
Knight Therapeutics 6.44 0 0% 14.18% Sep/05
J&J 178.43 -0.33 -0.18% 8.51% Sep/05
Eli Lilly 727.21 -15.70 -2.11% -19.48% Sep/05
Merck 84.71 0.66 0.79% -28.14% Sep/05
Novartis 103.98 0.06 0.06% 5.46% Sep/05
Novartis 129.82 1.34 1.04% 11.22% Sep/05
Pacira 26.45 -0.28 -1.05% 90.97% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
Supernus Pharmaceuticals 46.00 0.57 1.25% 35.93% Sep/05
TG Therapeutics 32.21 0.32 1.00% 46.21% Sep/05
Canopy Growth 2.02 0.11 5.76% -66.72% Sep/05
Alaunos Therapeutics 2.16 0 0% -10.74% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US2000 2391 11.44 0.48% 14.33% Sep/05

Corcept Therapeutics traded at $69.36 this Friday September 5th, decreasing $0.01 or 0.01 percent since the previous trading session. Looking back, over the last four weeks, Corcept Therapeutics lost 1.64 percent. Over the last 12 months, its price rose by 101.75 percent. Looking ahead, we forecast Corcept Therapeutics to be priced at 68.78 by the end of this quarter and at 67.09 in one year, according to Trading Economics global macro models projections and analysts expectations.

Corcept Therapeutics Incorporated is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the steroid hormone cortisol. The Company has marketed the cortisol modulator Korlym in the United States for the treatment of patients with a form of hypercortisolism known as endogenous Cushing’s syndrome. Cortisol activity can be modulated effectively by a drug that competes with cortisol as it attempts to bind to the glucocorticoid receptor (GR). The Company’s active ingredient, mifepristone, reduces the binding of excess cortisol to GR. Its portfolio of selective cortisol modulators consists of four structurally distinct series, including relacorilant, exicorilant and miricorilant. These compounds bind to GR but not the progesterone, estrogen or androgen receptors.